Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Karuna Therapeutics, Inc.

http://www.karunatx.com

Latest From Karuna Therapeutics, Inc.

ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund

ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups. 

Financing Innovation

Fears For Ukraine’s Access To Medicines And Trials As Russian Invasion Continues

The European pharma sector is looking to maintain supplies of essential medicines to Ukraine and Russia as invasion continues, while a US biopharma group is calling for industries to boycott all non-food and medical trade with Russia.

Ukraine Politics

Fears For Ukraine’s Access To Medicines And Trials As Russian Invasion Continues

The European pharma sector is looking to maintain supplies of essential medicines to Ukraine and Russia as invasion continues while a US biopharma group is calling for industry to boycott all non-food and medical trade with Russia.

Europe Ukraine

Cerevel Makes Progress, But Karuna Still One To Watch In Schizophrenia

Competition to bring new schizophrenia therapies to market is increasing, with the need to demonstrate side-effect improvements over existing drugs especially important.

Neurology Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register